

PATENT COOPERATION TREATY

FEB 19 2001

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

SIM & MCBURNEY
SMA HUGHES ASSOCIATES INC.

PCT

To:

RAE, Patricia, A.
Sim & McBurney
330 University Avenue
6th floor
Toronto, Ontario M5G 1R7
CANADA

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year) 15.02.2001

Applicant's or agent's file reference
6310-36 PAR

IMPORTANT NOTIFICATION

International application No.
PCT/CA99/01106

International filing date (day/month/year)
19/11/1999

Priority date (day/month/year)
19/11/1998

Applicant
THE UNIVERSITY OF WESTERN ONT..et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

 European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Exner, K

Tel.+49 89 2399-7826



THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

REC'D 20 FEB 2001

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 6310-36 PAR	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA99/01106	International filing date (day/month/year) 19/11/1999	Priority date (day/month/year) 19/11/1998
International Patent Classification (IPC) or national classification and IPC A61K31/202		
Applicant THE UNIVERSITY OF WESTERN ONT..et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 12 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 09/06/2000	Date of completion of this report 15.02.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Schnack, A Telephone No. +49 89 2399 8149



THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA99/01106

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

Description, pages:

1-42 as originally filed

Claims, No.:

1-16,17 (part), as originally filed
24-29

17 (part),18-23 as received on 15/11/2000 with letter of 15/11/2000

Drawings, sheets:

1/9-9/9 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/01106

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
 - ☐ translation of the earlier application whose priority has been claimed.
2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:
see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- ☐ the entire international application.
 - ☒ claims Nos. 9, 11, 17-26, 28, 29.

because:

- ☒ the said international application, or the said claims Nos. 9, 11, 17-26, 28, 29 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA99/01106

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .
2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2-4, 9-11, 13-15, 17, 18, 21-23, 25, 27
	No:	Claims	1, 5-8, 12, 16, 19, 20, 24, 26, 28, 29
Inventive step (IS)	Yes:	Claims	none
	No:	Claims	1-29
Industrial applicability (IA)	Yes:	Claims	1-8, 10, 12-16, 27
	No:	Claims	9, 11, 17-26, 28, 29, (see separate sheet)

2. Citations and explanations see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/01106

Reference is made to the following documents:

- D1: Developmental Biology, vol. 208, 1999, pp. 375-391
- D2: WO 99 244 15
- D3: WO 98 085 46
- D4: US 5 827 500
- D5: Patent Abstracts of Japan, PN no: 10114757
- D6: Fundamental and Applied Toxicology, vol. 34, 1996, pp. 91-98.
- D7: Molecular Biology of the Cell, vol. 8, no. suppl., pp 71a.
- D8: Int. J. Dev. Biol., vol. 39, 1995, pp. 617-627.
- D9: Teratology, vol. 50, 1994, pp. 54-62

Section II
Priority

The present priority right has been checked and found invalid for the subject matter according to present claims 2-6, 8, 12-25 and 27. The subject matter according to these claims is not appear to be disclosed in the priority document (CA02254429), and consequently such subject matter does not enjoy the priority right. Thus, subject matter, which is not disclosed in the priority document, enjoys an effective date of filing of 19.11.1999. For such subject matter, the documents D1 and D2 are prepublished prior art and can be used in the assessment of patentability of the present subject matter.

Concerning claims 2-4: the present priority document discloses on page 8, lines 19-21 compositions comprising RAR antagonists and other chondrogenic stimulators, e.g. BMPs. This disclosure does not amount to a specific disclosure of OPS and a cytokine and combinations thereof as well as specific BMPs, (BMP-2, BMP-4, BMP-5) and a specific OPS, (OPS-1).

Concerning claim 5: nowhere in the present priority application is stated that the RAR antagonist is present "in an amount capable of stimulating chondrogenesis and associated differentiation of skeletal progenitor cells".

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/01106

- Concerning claim 6: the present priority document discloses on page 7, lines 27-28 that the present composition "is applied locally to a fracture site, for example by means of a biodegradable sponge, gel or paste". This does not amount to a disclosure of "a solution, suspension, matrix, film, pill, tablet or encapsulated within liposomes" as claimed in present claim 6.
- Concerning claim 8: the present priority document discloses on page 7, line 26-28 administration by means of "a biodegradable sponge, gel or paste". This does not amount to a generalisation to any biodegradable implantable matrix.
- Concerning claims 12-15: the present priority document does not on page 7, lines 26-30 explicitly disclose "a morphogenic device for implantation in a vertebrate comprising an implantable biocompatible carrier and a RAR antagonist dispersed within or on said carrier".
- Concerning claim 16: the present priority document discloses on page 8, lines 10-18 that chondrogenic cells or cells with chondrogenic potential can be expanded in-vitro. This does not amount to an explicit disclosure of producing a chondrocyte from a chondroprognitor mesenchymal cell as presently claimed.
- Concerning claims 17,18: the present priority document discloses on page 7, lines 29-30 "treatment with the present compositions of orthopedic or dental implants to enhance or accelerate osseous integration". This sentence cannot form basis for the specified method according to present claim 17, since a general disclosure cannot be used to form basis for a detailed and specific disclosure.
- Concerning claims 19-25, 27: applicant claims that the subject matter of these claims

THIS PAGE BLANK (USPTO)

are supported on pages 7-8 of the priority document. The present IPEA considers that such subject matter is not explicitly disclosed on these pages. Nowhere is "treatment of a cartilage associated degenerative condition" as claimed in claim 19 explicitly disclosed. It is not enough to disclose only one cartilage associated degenerative condition and then generalise this to any cartilage associated degenerative condition.

The subject matter of present claims 20-25 and 27 does not find basis in the priority application on pages 7-8, since said priority document does not explicitly disclose the features of these claims.

In conclusion, the subject matter of present claims 2-6, 8, 12-25 and 27 does not enjoy the presently claimed priority right and the effective date of an assessment of patentability of the subject matter according to these claims would be the international filing date 19.11.1999. Thus, D1 and D2 are republished documents.

Section III

Non-establishment of opinion

The present claims 1-29 have not been searched completely, (see search report). Thus, this written opinion is only based on the subject matter, which has been searched i.e. the parts of the present claims, which is clear, supported and disclosed; namely those parts relating to the compounds structurally identified in the description, pp. 15-16.

Claims 9, 11, 17-26, 28 and 29 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

THIS PAGE BLANK (USPTO)

Section V

V.1. Novelty

Objections under Article 33(2) PCT:

Present claims 1-8 and 12-15 and 27 relate to compositions and devices comprising an RAR antagonist. Compositions comprising RAR antagonists do not appear to be novel, (see D1-D3, the passages indicated in the search report, D4, the passage indicated in the search report and claim 7, D5, the whole document, D6, the passages indicated in the search report and D7, the whole document). Thus, the subject matter according to present claims 1, 5-8, 12, 15 and 27 does not appear to be novel with respect to the mentioned documents. In this context it is pointed out that the intended purpose of a pharmaceutical composition is not considered to be a technical feature that would distinguish such a composition from any known pharmaceutical preparation comprising the same ingredients.

Moreover, D1 discloses administration of RAR antagonists as a part of an implant. The studies according to D1 is conducted in order to establish the role of retinoid signalling for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. It is concluded that retinoid dependent and RAR mediated mechanisms are required for completion of the chondrocyte maturation process and endochondral ossification in the developing limb, (see D1, the abstract and the passages indicated in the search report). Thus, the subject matter of present claims 5, 6, 8, 12, 16, 20, 28 and 29 appears to lack novelty over the disclosure in D1.

Present claims 9-11, 16-26 and 28-29 relate to uses or methods of treatment involving RAR antagonists. All the present uses and methods appear to be based on the observation that RAR antagonists can act as stimulators of chondrogenesis and skeletal development, (cf. present application, page 8, lines 18-19). However, this observation does not appear to be novel, since at least some earlier studies have shown this, (cf. present application, page 1, line 15 - page 2, line 10 and see D1, D8 and D9 the passages indicated in the search reports). Thus, the observation that RAR antagonists are able to stimulate chondrogenesis and skeletal development cannot be regarded as a novel observation even though it may be true that other studies have demonstrated the opposite, which has resulted in inconsistency and uncertainty as to which of the effects was "correct". In this context it is further emphasized that since it

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/01106

appears that there exist situations, where RAR antagonists work to stimulate chondrogenesis and skeletal development as well as situations, where RAR antagonists work to inhibit chondrogenesis and skeletal development, (cf. present application, page 2, lines 7-10), the present claims lack essential features explaining in which situations the RAR antagonists work as stimulators of chondrogenesis and skeletal development. Moreover, applicant states in his letter of reply that "in the present application the applicant has found that inhibition of a single RAR was not sufficient to promote chondrogenesis, as has been shown in D8". Applicant further admits that D8 discloses that "antagonism of RAR-mediated signalling regulates chondrogenesis by enhancing the formation of precartilaginous condensations". However, if inhibition of a single RAR is not enough to solve the technical problem, then essential technical features must be missing in the present claims.

Applicant has in his letter of reply aimed at explaining this difference, however, no amendments to the claims have been made. It is emphasized that it is the claims, which form basis for establishment of the present opinion on novelty and inventive step and it is not relevant to discuss features, which are not present in the claims. The use of a composition comprising a RAR antagonist for promoting chondrogenesis is as explained above not novel over the disclosures in D1, D8 and D9.

Applicant alleges that what is presently observed is that RAR antagonists promote chondroblast differentiation in the early stage of the chondrogenic process, whereas they inhibit chondrocyte maturation later on. However, D7 also aims at explaining the different effects of RAR antagonists during development of chondrocytes, (see D7, the entire document), even though it appears that D7 demonstrates the opposite as presently alleged. This once again stresses the importance of specifying in the claims, when stimulation of chondrogenesis occurs.

As stated in D8 page 621, col. 2, paragraph 2, "Inhibition of chondrogenesis by RA such as shown here is well known but the mechanism remains unresolved". antagonizing the RAR in order to stimulate chondrogenesis is not novel or at least not inventive. Elucidation of the mechanism behind such a stimulation cannot be considered to be an invention, but is rather considered to be a discovery. An invention must make a contribution to the art in the sense that medical professionals must be presented with information, which would urge them to change the treatment of their

THIS PAGE BLANK (USPTO)

patients; not just explain why the already existing treatment works.

It is true that the studies according to D8 are done with antisense oligodeoxynucleotides and not with RAR antagonists, (see D8, page 623, col 1, line 7 from bottom - col. 2, line 2). However, even if such a difference would render the subject matter of the present claims novel, it is not considered to involve an inventive step, since the general teaching that interrupting the RA-RAR interaction leads to stimulation of chondrogenesis is not novel. Interruption of the RA-RAR interaction by use of RAR antagonists is also not novel.

Moreover, D3 teaches the use of RAR antagonists for the treatment of rheumatoid arthritis, (see D3, the passages indicated in the search report). Thus, the subject matter of at least present claims 19, 24 and 26 appears to lack novelty with respect to D3.

D4 teaches the use of RAR antagonists for the treatment of rheumatic and bone disorders, (see D4, the passages indicated in the search report). Thus, the subject matter of at least present claims 19, 24 and 26 appears to lack novelty with respect to D4.

V.2. Inventive step

Objections under Article 33(3) PCT:

Novel subject matter falling within the scope of present claims 1-29 does not appear to involve an inventive step, the reasons being as follows: It is already known that inhibition of expression of the genes for RAR receptors enhances chondrogenesis, (see D8), that RAR agonists inhibit cartilage differentiation, (see D9), that down regulation of RAR is important for chondrogenic expression (cf. present page 1, lines 15-16) and that RAR specific agonists inhibit cartilage formation in limb bud micromass cultures and negatively affects skeletal development, (cf. present page 1, lines 25-28). Thus, it does not require inventive skills to speculate that RAR antagonists could be useful in the treatment of diseases and conditions, where cartilage or bone need to be developed or restored, such as the diseases or conditions mentioned in present claims 19-26 and 28-29.

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/01106

V.3. Industrial applicability

Remarks under Article 33(3) PCT:

For the assessment of the present claims 9, 11, 17-26, 28 and 29 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Section VI

The following document may become relevant in the subsequent national/regional phase:

	Priority date:	Filing date:	Publication date:
D2:	12.11.97	12.11.98	20.05.99

Section VIII

Remarks under Article 5 and 6 PCT:

Present claims 1-29 relate to compounds defined by reference to a desirable pharmacological property, namely the activity as antagonist of retinoic acid receptor. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. Thus, the present claims do not define the subject matter in terms of technical/structural features, but rather aim at defining the scope of the claims through a desired result to be achieved. Thus, the present claims do not meet the requirements of Article 5 and 6 PCT.

The subject matter of present claims 2-5 is so poorly supported by the description and the examples that such subject matter can only be considered to be speculative. No



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/01106

support appears to be found for compositions according to these claims, neither is any effect of such compositions disclosed.

Present claim 7 aims at defining a composition through an administration route. However, an administration route does not characterize a composition as such, for which reason this claim is unclear.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



REPLACED BY
ART 34 AMDT

for a time sufficient to permit enhanced tissue growth between the target cartilage tissue and the device.

18. The method according to claim 19, wherein said target tissue is cartilage or bone.

19. A method of treating a cartilage associated degenerative condition in a vertebrate comprising the step of administering a pharmaceutical composition as claimed in claim 1.

20. A method for promoting chondrogenesis and associated bone tissue formation at a site of skeletal surgery in a vertebrate, the method comprising the steps of delivering an RAR antagonist composition at the site of skeletal surgery wherein such delivery promotes the formation of new bone tissue.

21. A method for repairing large segmental skeletal gaps and non-union fractures arising from trauma or surgery in vertebrates, the method comprising delivering a RAR antagonist composition at the site of the segmental skeletal gap or non-union fracture wherein such delivery promotes chondrogenesis which mediates the formation of new bone tissue.

22. A method for aiding the attachment of implantable prosthesis at cartilagenous sites and for maintaining the long term stability of the prostheses in vertebrates, the method comprising coating selected regions of an implantable prosthesis with a RAR antagonist composition and implanting the coated prosthesis into a cartilagenous site wherein such implantation promotes the formation of new cartilage tissue.

23. A method of producing cartilage at a cartilage defect *in vivo*, said method comprising:

- implanting into the defect a population of chondrogenic cells which have been cultured in the presence of a RAR antagonist.



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/202, 31/203, 31/352, 31/192, 31/381, 31/196, 31/655, 31/382, 31/235, A61P 19/02, 19/08	A1	(11) International Publication Number: WO 00/30635 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/CA99/01106 (22) International Filing Date: 19 November 1999 (19.11.99) (30) Priority Data: 2,254,429 19 November 1998 (19.11.98) CA (71) Applicant (for all designated States except US): THE UNIVERSITY OF WESTERN ONTARIO [CA/CA]; Office of Industry Liaison, Stevenson-Lawson Building, Room 319, London, Ontario N6A 5B8 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): UNDERHILL, Tully, Michael [CA/CA]; The University of Western Ontario, Division of Oral Biology, School of Dentistry, London, Ontario N6A 5C1 (CA). WESTON, Andrea, Dawn [CA/CA]; The University of Western Ontario, The Faculty of Medicine & Dentistry, Department of Physiology, London, Ontario N6A 5C1 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS		
(57) Abstract The invention provides compositions comprising a RAR antagonist for promoting chondrogenesis and to methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for <i>ex vivo</i> tissue engineering.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS

Field of the Invention

5 The invention relates to compositions for promoting chondrogenesis and to methods for treating cartilage and bone abnormalities resulting from injury or disease and for *ex vivo* tissue engineering.

Background of the Invention

10 Retinoic acid (RA) is known to have an important signalling role in the regulation of embryonic development and cell differentiation. The biological effects of RA are transduced via two classes of nuclear receptors, designated retinoic acid receptors (RAR α , RAR β and RAR γ) and retinoid X receptors (RXR α , RXR β and RXR γ) (Giguere et al., (1987), Nature, 350, 624-629).

15 Many studies have been made of the role of RA and its receptors in the process of chondrogenesis and skeletal development. For example, down regulation of RAR α has been stated to be important for chondrogenic expression (Cash et al, 1997). Down regulation of RAR- β 2 using antisense oligonucleotides was found to stimulate chondrogenesis and thus it was suggested that RAR- β 2 helps to prevent
20 mesenchymal cells from expressing their chondrogenic bias (Jiang et al., 1995). Underhill et al 1998 reported that abnormal expression of RARs inhibits chondrogenesis. However, it was also found that absence of RAR can lead to deficiencies in cartilage formation while also promoting chondrogenesis at ectopic sites.

25 Addition of RA and RAR-specific agonists has been shown to inhibit cartilage formation in limb bud micromass cultures, and act as a teratogen *in vivo* to negatively affect skeletal development (Kistler, 1987; Kochhar, 1973; Kochhar and Aydelotte, 1974; Kwasigroch and Kochhar, 1980). In contrast, addition of retinoic acid to micromass cultures has also been demonstrated to stimulate cartilage formation (Ide
30 and Aono, 1988; Paulsen et al., 1994a; Paulsen et al., 1994b).

Addition of an RAR antagonist completely reversed the inhibitory action of an RAR agonist on chondrocyte differentiation in rat and mouse embryo limb bud mesenchymal cells *in vitro* (Eckhardt et al., (1994), Toxicol. Letters, 70, 299-308; Kocchar et al., (1998), Int. J. Dev. Biol., 42, 601-608). These authors, however, found that the antagonist alone had no effect on limb bud mesenchymal cell differentiation.

The precise role of RARs in chondrogenesis was unclear from these studies. Specifically, it was unclear whether RARs functioned to inhibit chondrogenesis or stimulate that process. Overall, the role of RAR antagonists in the process of chondrogenesis was not clearly established.

Summary of the Invention

It has now been demonstrated that RAR activity alone has a fundamental role in controlling the transition of chondroprogenitor cells into chondrocytes. It has also now been demonstrated that administration of RAR antagonists can initiate chondrogenesis and stimulate cartilage formation *in vitro* and *in vivo*. Furthermore, it is now also demonstrated that administration of a RAR antagonist can rescue cartilage formation. This provides a basis for the development of therapeutic compositions and uses of such compositions to treat disorders involving abnormal cartilage formation.

The present invention now provides therapeutic compositions and methods for the treatment of disorders involving abnormal cartilage formation and associated abnormal skeletal development resulting from disease or due to trauma.

In accordance with one embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of an RAR antagonist and, optionally, a pharmaceutically acceptable carrier.

RAR antagonists for use in the present invention are characterized by having a stimulating effect on cartilage formation and as a result on associated bone development in a vertebrate. RAR antagonists may be defined as any chemical that binds to one or more of the RAR subtypes with a K_d of less than 1 micromolar. Conventionally, a RAR antagonist is a chemical agent that inhibits the activity of an RAR agonist.

In accordance with a further embodiment, the invention provides a method for stimulating cartilage formation in a vertebrate, the method comprising administering to the vertebrate an effective cartilage formation stimulating amount of an RAR antagonist.

5 In accordance with a further embodiment, the invention provides a method for treating damaged cartilage and associated bone in a subject, comprising administering to the subject an effective amount of an RAR antagonist, wherein the RAR antagonist stimulates cartilage repair and formation which mediates associated bone repair.

10 In accordance with a further embodiment, the invention provides a method for enhancing osseous integration of orthopedic or dental implants in a subject comprising administering to the subject an effective amount of an RAR antagonist.

In accordance with a further embodiment, the invention provides a method for treating arthritis in a subject, comprising administering to the subject an effective amount of an RAR antagonist.

15 In accordance with a further embodiment, the invention provides a method for treating arthritis in a subject, comprising administering to the subject chondrogenic cells treated with an effective amount of an RAR antagonist.

According to one embodiment of the invention, there is provided a composition for inducing chondrogenesis and associated skeletal development in a vertebrate, the composition comprising:

- a RAR antagonist; and
- a pharmaceutically acceptable carrier.

20 According to another embodiment of the invention, there is provided a morphogenic device for implantation at a cartilage site in a vertebrate, the device comprising:

- an implantable biocompatible carrier; and
- a RAR antagonist dispersed within or on said carrier.

25 According to yet another embodiment of the invention, there is provided the use of a composition comprising a RAR antagonist and a pharmaceutically acceptable carrier, for inducing chondrogenesis *in vitro*.

30 According to yet another embodiment of the invention, there is provided a method for producing a chondrocyte from a chondroprogenitor mesenchymal cell

comprising contacting a chondroprogenitor mesenchymal cell with a RAR antagonist *in vitro*.

According to another embodiment of the invention, there is provided an implantable prosthetic device for repairing cartilage-associated orthopedic defects, injuries or anomalies in a vertebrae, the device comprising:

- a prosthetic implant having a surface region implantable adjacent to or within a cartilage tissue.

- a RAR antagonist composition disposed on the surface region in an amount sufficient to promote enhanced cartilage growth into the surface.

According to another embodiment of the invention, there is provided a method for promoting *in vivo* integration of an implantable prosthetic device into a target cartilage tissue of a vertebrae, the method comprising the steps of:

- providing on a surface of the prosthetic device a composition comprising a RAR antagonist and a pharmaceutically acceptable carrier and

- implanting the device in a vertebrae at a site where the target cartilage tissue and the surface of the prosthetic device are maintained at least partially in contact for a time sufficient to permit tissue growth between the target cartilage tissue and the device.

According to yet another embodiment of the invention, there is provided a method for promoting natural bone formation at a site of skeletal surgery in a vertebrae, the method comprising the steps of delivering a RAR antagonist composition to the site of the skeletal surgery whereby such delivery indirectly promotes the formation of new bone tissue mediated by cartilage.

According to another embodiment of the invention, there is provided a method for repairing large segmental skeletal gaps and non-union fractures arising from trauma or surgery in a vertebrae, the method comprising delivering a RAR antagonist composition to the site of the segmental skeletal gap or non-union fracture whereby such delivery promotes the formation of cartilage which mediates new bone tissue formation.

According to yet another embodiment of the invention, there is provided a method for aiding the attachment of an implantable prosthesis to a cartilage site and for maintaining the long term stability of the prosthesis in a vertebrae, the method

comprising coating selected regions of an implantable prosthesis with a RAR antagonist composition and implanting the coated prosthesis into the cartilage site, whereby such implantation promotes the formation of new cartilage tissue and indirectly stimulates bone formation.

5 According to a further embodiment of the invention, there is provided a method of producing cartilage at a cartilage defect site *in vivo*, the method comprising:

- implanting into the defect site a population of chondrogenic cells which have been cultured *in vitro* in the presence of a RAR antagonist.

10 According to another embodiment of the invention, there is provided a method for treating a degenerative joint disease characterized by cartilage degeneration, the method comprising:

- delivering a therapeutically effective amount of a RAR antagonist to a disease site.

15

Summary of the Drawings

The present invention will be further understood from the following description with reference to the Figures, in which:

20 Figure 1 shows photomicrographs of transgene-expressing cells. Panels (A-C) show wild-type fore limb cultures stained with alcian blue on days 2, 4 and 6. Panels (D-G) show transgenic fore limb cultures stained with magental-gal followed by alcian blue at days 2, 4 and 6. Panel (D) shows higher magnification of day 4 transgenic fore limb cultures. Transgene-expressing cells are excluded from the cartilage nodules. Panel (H) shows day 4 transgenic hind limb cultures. Transgene-expressing cells are much more abundant compared to fore limb cultures, and hence only a few small cartilage nodules have formed. Bar: (A-C, E-H) 1.0 mm (D) 0.4 mm.

30 Figure 2A shows photomicrographs of transgene-expressing cells. Panels (A-H) show whole mount *in situ* hybridization of wild-type and transgenic cultures carried out using probes characteristic of specific stages of chondrogenesis. Panel (A)

shows Col II expression is very abundant in wild-type cultures. Panel (B) shows Col II expression in transgenic cultures is much weaker and has a more widespread distribution. Panels (C, E, G) show wild-type cultures, N-cad, gli-1, and col I are all abundantly expressed in perinodular regions but are only weakly expressed in the core of the nodules. Panels (D, F, H) show that in transgenic cultures, N-cad, gli-1 and col-I are expressed throughout the cultures with no apparent downregulation as seen in the center of the nodules of wild-type cultures. Bar: (A-H) 0.4 mm.

Figure 2B shows the results of northern blot analysis using total hind limb bud RNA indicating that col II is downregulated in transgenic hind limbs at E 14.5, and gli-1 is downregulated in transgenic hind limbs at E 12.5.

Figure 3 shows transgene-expressing cells respond differently to BMP-2. Panel (A) shows quantitative analysis of nodule formation *in vitro*. There are fewer cartilage nodules in the fore and hind limb cultures of untreated transgenic cultures compared to those in untreated wild-type cultures. BMP-2 treatment increases the number of nodules in both wild-type and transgenic cultures, however, the increase seen in wild-type cultures is more dramatic. Panels (B-D) show wild-type cultures treated with BMP-2 stained with alcian blue at days 2, 4 and 6. In response to BMP-2, there is a noticeable increase in nodule number and in nodule size, with cartilage nodules located at the periphery of the cultures becoming the largest. Panels (F-H) show transgenic cultures treated with BMP-2 and stained with magenta-gal followed by alcian blue at days 2, 4 and 6. In response to BMP-2 there is an increase in nodule number and in nodule size. There are also many more condensations of transgene-expressing cells. Panel (E) shows higher magnification of day 4 wild-type cultures treated with BMP-2. Panel (I) shows higher magnification of day 4 transgenic cultures treated with BMP-2. BMP-2 stimulates condensation of transgene-expressing cells, but they remain excluded from cartilage nodules. Bar: (A-C, E-G) 1.0 mm (D, H) 0.4 mm.

30

Figure 4 shows Col II expression is altered in transgenic cultures. Panels (A, B) show Col II expression in wild-type and transgenic cultures respectively. In wild-

type cultures, col II is abundantly expressed within cartilage nodules and is much weaker in transgenic cultures with a less distinct expression pattern. Panel (C) shows that in response to BMP-2 the number of cartilage nodules in wild-type cultures that express col II abundantly increases. Panel (D) shows that in transgenic cultures treated with BMP-2 there are a few nodules with abundant col II expression and several condensations with weaker expression. Bar: (A-D) 0.4 mm.

Figure 5 shows BMP-2 and AGN194301 exhibit different chondrogenic stimulatory properties. Panel (A) shows untreated wild-type cultures stained with alcian blue on day 6. Panels (B, C) show wild-type cultures treated with BMP-2 for the first two days and three days of culture, respectively, and stained with alcian blue on day 6. These cultures resemble untreated cultures. Panel (D) shows wild-type cultures treated continuously with BMP-2 and stained with alcian blue on day 6. Panels (E, F) show wild-type cultures were treated after two or three days respectively and stained with alcian blue on day 6. These cultures resemble cultures that were treated continuously with BMP-2. Panel (G) shows untreated wild-type cultures stained with alcian blue on day 8. Panels (H, I) show wild-type cultures treated with AGN194301 for the first two days and three days of culture, respectively, and stained with alcian blue on day 8. These cultures resemble cultures treated continuously with AGN194301 in that there are several more smaller nodules. Panel (J) shows wild-type cultures were treated continuously with AGN194301 and stained with alcian blue on day 8. Panels (K, L) show wild-type cultures treated after two or three days respectively and stained with alcian blue at day 8. The size and number of cartilage nodules is less compared to cultures treated continuously. Bar: (A-L) 1.0 mm. Panel (M) shows quantification of cartilage nodule formation in response to BMP-2 and AGN194301. In response to BMP-2, or AGN194301 alone, there is a dramatic increase in the number of nodules that form. When BMP-2 and AGN194301 are added together, the number of nodules formed is greater than when each is added alone.

Figure 6 shows the rescue of cartilage formation in Noggin-treated cultures by addition of AGN194301. Panel (a) shows wild-type cultures stained with alcian blue

on day 6. Panel (b) shows wild-type cultures treated with Noggin (10ng/ml) and stained with alcian blue on day 6. In comparison to control cultures, only a few weakly stained nodules are evident and these are present within the center of the culture where cell density is highest. Panel (c) shows wild-type cultures treated with 10ng/ml Noggin and 1 μ M AGN194301. When Noggin and AGN 194301 are added together, there is no apparent decrease in nodule formation in comparison to untreated cultures. Similar to that observed in control cultures, nodules are distributed throughout the culture. Panel (d) shows the quantification of cartilage nodule formation in response to Noggin and AGN194301. Treatment of Noggin alone dramatically reduced the number of cartilage nodules to ~10% of that of control cultures. Addition of AGN194301 to Noggin-treated cultures rescues cartilage formation and leads to an increase in cartilage nodule formation comparable to that of control cultures. Panels (e, f) show the analysis of col IIa and col II expression in Noggin-treated cultures, respectively, revealing a comparable number of col 2a expressing aggregates and col II expressing nodules. The bar represents 1 mm.

Detailed Description of the Invention

The present inventors have demonstrated the use and effectiveness of RAR antagonists to stimulate chondrogenesis and skeletal development.

Limb Bud Development

Patterning of the vertebrate limb bud relies on the cooperative action of several signalling centres. Signals have been identified that emanate from the apical ectodermal ridge (AER), ventral ectoderm (VE) and a region within the distal posterior margin termed the zone of polarizing activity (ZPA). The AER is important in specifying proximodistal axial identity, while the VE and ZPA are important in determining dorsal/ventral and anteroposterior identity, respectively. Each is essential for the proper patterning and outgrowth of the limb, and their perturbation results in defects of the paraxial skeleton. The mechanism by which these patterning cues influence mesenchyme commitment is thought to occur within the progress zone (PZ) which underlies the AER. Cells within the progress zone receive signals from all three signaling centres, integrating them into a positional identity that is fixed as the

cells leave the PZ during limb outgrowth. Shortly thereafter this positional identity is translated into a cell identity and the corresponding differentiation program is initiated. With respect to skeletal formation, these signals culminate in the commitment of mesenchymal cells to the chondrocytic lineage.

5 Bones within the limb are formed from a cartilage precursor and the cartilage forms from condensed mesoderm. These condensations represent the earliest stages of limb patterning and are considered to be the forbears of the mature limb bones (Ede, 1983). Following condensation, the mesodermal cells in the interior of each condensation differentiate into chondrocytes. This differentiation occurs in concert
10 with limb outgrowth, such that proximal mesenchymal cells (close to the body wall) that are fated to become chondrocytes differentiate prior to more distal cells. The spatiotemporal regulation of mesenchyme differentiation into chondrocytes is a crucial step in endochondral bone formation in that it preserves the pattern of the bone primordia established earlier in limb development and provides a suitable matrix for
15 subsequent ossification. Despite the importance of this stage in skeletal development, mechanisms that control mesenchyme differentiation into chondrocytes are poorly understood.

 During limb outgrowth, signals that promote as well as inhibit chondrogenesis are important determinants in limb ontogeny (Wolpert, 1990). Many molecules have
20 been identified that promote chondrogenesis *in vivo* and *in vitro*. Some of these include members of the transforming growth factor (TGF)- β superfamily, bone morphogenetic proteins (BMPs), *gdf-5*, and TGF- β -1, -2 and -3 (Hogan, 1996; Kingsley, 1994; Moses and Serra, 1996; Wozney and Rosen, 1998). The importance of *bmp-5* and *gdf-5* in limb development is illustrated by the recent mapping of the
25 classical mouse mutations for short ear and brachypod to their respective loci (Kingsley et al., 1992; Storm et al., 1994). Both of these mutants exhibit malformations in appendicular skeletal formation which, for the case of brachypod, has been attributed to a defect in chondrogenesis (Duke and Elmer, 1977). Mice deficient in BMP-6 or BMP-7 also present with skeletal defects including delay in the
30 ossification of the sternum in *bmp-6* *-/-* animals (Solloway et al., 1998) and polydactyly in the hind limbs of *bmp-7* *-/-* animals (Luo et al., 1995). *Bmp-2* and -4 are expressed in condensing mesenchyme early in limb development then become

localized to the interdigital mesenchyme and perichondrium (Jones et al., 1991; Lyons et al., 1990; Rosen et al., 1989). Mouse embryos devoid of BMP-2 or BMP-4 do not survive beyond E9.5 (Winnier et al., 1995; Zhang and Bradley, 1996) making it difficult to elucidate their exact roles in skeletal development. It is known, however, that exogenously added BMP-2 or -4 under certain circumstances leads to overgrowth of the limb cartilages (Duprez et al., 1996; Duprez et al., 1996). Loss or gain-of-function of noggin, an inhibitor of BMP-2, -4 and -7, contributes to either overgrowth or a reduction in limb cartilages, respectively (Brunet et al., 1998; Capdevila and Johnson, 1998). Together, these observations suggest an important role for the BMPs, especially BMPs -2 and -4 in formation of the cartilaginous elements of the limb bud.

It is well established that retinoic acid (RA), the active derivative of vitamin A is essential for normal embryonic development. Exposure of embryos to excess RA results in a range of defects depending not only on the dose of RA, but also on the timing of its administration (Shenefeldt, 1972). For instance when administered to E 11.5 to E 14.5 mouse embryos, large doses of RA cause limb defects (Kochhar, 1973; Kwasigroch and Kochhar, 1980). This period during which RA treatment has the most dramatic effects on limb formation coincides with the timing of chondrogenesis in the limb bud.

RA exerts most of its biological effects primarily through receptors belonging to the steroid hormone family of nuclear receptors. There are two subfamilies of nuclear retinoid receptors, the RA receptors (RARs) and the retinoid X receptors (RXRs), with three subtypes of each (α , β , and λ) (Chambon, 1996; Mangelsdorf et al., 1994). All three subtypes of the RARs have been suggested to have some role in chondrogenesis (Underhill and Weston, 1998). The expression patterns of the RARs in the developing limb are consistent with their proposed roles in skeletal formation. Between E9.5 and E11.5, RAR α and λ are expressed throughout the limb mesenchyme (Dolle et al., 1989; Ruberte et al., 1990). Beyond this stage, RAR α is downregulated within the cartilaginous areas, while RAR λ expression remains localized to these areas. RAR α expression becomes restricted to the interdigital region (IDR) overlapping with RAR β expression at this time, and is also present in

the perichondrium. In addition to being present in the IDR, RAR β is expressed in the interior, anterior, and posterior necrotic zones (Dolle et al., 1989; Mendelsohn et al., 1991). While null mutants of either RAR α , RAR β or RAR λ exhibit no limb skeletal malformations (Ghyselinck et al., 1997; Lohnes et al., 1993; Lufkin et al., 1993; Luo et al., 1995), compound homozygous null alleles of RAR α and RAR λ exhibit a range of severe limb abnormalities from reductions to duplications (Lohnes et al., 1994). Thus, these results demonstrate an important function for the RARs in skeletal development.

To further explore RAR function in limb development the present inventors have used an existing transgenic line of mice that overexpress a weak constitutively active RAR α 1 (caRAR α) in the developing limb bud (Cash et al., 1997). Transgenic animals present with a number of limb skeletal abnormalities as a result of transgene-mediated inhibition of cartilage formation. Transgene-expressing cells do not differentiate into chondroblasts, but instead remain as condensed mesenchyme. Conversely, an RAR α antagonist was demonstrated to stimulate cartilage formation in wild-type limb mesenchymal cultures. Addition of BMP-2 or -4 to *in vitro* cultures of transgenic mesenchyme dramatically stimulated condensation of transgene-expressing mesenchymal cells but failed to induce chondroblast differentiation. More importantly, addition of this antagonist was found to rescue chondrogenesis in noggin treated wild-type cultures. Taken together, the results demonstrate that loss of RAR activity is necessary, and supersedes the requirement of BMPs, for chondroblast differentiation during limb outgrowth.

Regulation of chondroblast differentiation is critical for the proper formation of the appendicular skeleton. Herein it is now demonstrated that RAR activity has a fundamental role in controlling the transition of prechondrogenic cells to chondroblasts, and that the loss of RAR activity stimulates cartilage formation. The importance of RARs in mediating chondroblast differentiation is further exemplified by the observations that addition of BMP-2 and -4 is not sufficient to rescue RAR α expressing prechondrogenic cells, while an RAR α specific antagonist is able to rescue cartilage formation in noggin-treated cultures. Therefore, BMPs and RARs function

in a sequential manner to orchestrate chondroblast differentiation during limb bud outgrowth.

Function of RARs during skeletal development

- 5 Overexpression of a caRAR α in limb mesenchyme inhibits chondroblast differentiation and maintains the prechondrogenic cell phenotype. The phenotype of cells expressing the transgene is consistent with that of condensed mesenchymal cells and perichondrial cells. Both of these cell types are similar in that they are chondroprogenitors which have not yet undergone chondroblast differentiation.
- 10 Condensed mesenchymal cells and perichondrial cells both have continued expression of N-cadherin, gli-1, and col-I but express col II only weakly, a pattern of expression that is seen in transgenic cultures. The normal expression pattern of RAR α in the developing limb is consistent with its absence being essential for the transition from a chondroprogenitor to a chondroblast. RAR α is expressed in the prechondrogenic
- 15 condensations, the perichondrium, and in the interdigital region, but is downregulated in newly formed cartilaginous elements. The importance of the loss of RAR α signal is further demonstrated by experiments in which the RAR α specific antagonist AGN194301 increased cartilage nodule formation in primary cultures by 60%. Hence, the proper regulation of RAR α activity is essential for normal cartilage development.
- 20 Surprisingly, RAR α null mutants display no overt skeletal malformations of the appendicular skeleton with the exception that a certain proportion (approx. 60% of animals surviving to 1-2 months of age) of RAR α null mutants have webbed digits (Lohnes et al., 1993; Lufkin et al., 1993). However, in micromass cultures, attenuation of RAR α 2 expression with an anti-sense oligonucleotide to RAR α 2
- 25 stimulated cartilage formation *in vitro* (Jiang et al., 1995). This suggests that RAR α alone is not essential for the maintenance of the prechondrogenic cell fate, but one of the RARs may be able to substitute for this function, the most likely candidate being RAR γ . RAR γ null mutants also have no obvious appendicular skeletal malformations. RAR α /RAR γ compound homozygous mutants, however, exhibit a
- 30 number of skeletal defects including reductions, duplications, and to a lesser extent, ectopic cartilage formation within the interdigital region (Lohnes et al., 1994).

Ectopic cartilages are also observed at a number of additional sites in these animals including the meninges, peritoneum, diaphragm, and semi-lunar cusps of the heart (Lohnes et al., 1994; Mendelsohn et al., 1994). In addition, the phalangeal joints of these animals are malformed. While $RAR\alpha/\beta$ and $RAR\beta/\gamma$ double knockouts exhibit
5 some cartilaginous deficiencies, they do not present with any appendicular skeletal defects. More importantly, the skeletal defects in the $RAR\alpha/\gamma$ double knockouts can be rescued, for the most part, by the single allele of $RAR\alpha2$.

Results from knockout studies combined with the *in vivo* expression patterns of RARs suggest that both $RAR\alpha$ and $RAR\gamma$ are important in regulating chondroblast
10 differentiation in the limb. $RAR\beta$ knockouts exhibit no skeletal abnormalities, and $RAR\beta$ mRNA is absent in precartilaginous condensations during limb ontogeny (Ghyselinick et al., 1997). Thus, the combined activity of $RAR\alpha$ and $RAR\gamma$, but not $RAR\beta$ is likely involved in regulating cartilage differentiation in the limb bud. In other areas of the developing embryo, chondrogenesis may also rely on the actions of
15 specific combinations of RARs.

Sequential action of BMPs and RARs in skeletal development

The BMPs have been shown to be important in many aspects of endochondral bone formation including the commitment and differentiation of mesenchymal cells to
20 the chondrocytic lineage. During limb outgrowth *bmp-2/-4* are expressed within the condensing mesenchyme, the perichondrium and the interdigital region (Jones et al., 1991; Lyons et al., 1990; Rosen et al., 1996). Unfortunately, null mutants have not been informative in sorting out the function of BMPs-2/-4 in these regions (Winnier et al., 1995; Zhang and Bradley, 1996). Additional studies, utilizing dominant-negative
25 or constitutively active BMP type II receptors *in vitro* and *in vivo* have demonstrated, however, that BMP signaling (most likely BMP-2 and 4) is a requisite step in cartilage formation (Zou et al., 1997). These observations have been complemented by experiments in which BMPs were overexpressed in the developing chick limb. It has been demonstrated that the BMPs can stimulate cartilage formation (Duprez et al.,
30 1996; Duprez et al., 1996) and modify skeletal element patterning in addition to stimulating apoptosis within the interdigital region (Macias et al., 1997; Yokouchi et

al., 1996). Furthermore, loss or gain of function studies with noggin, an inhibitor of BMP-2 and -4 with lower affinity for BMP-7, has shown that BMP-2 and -4 are important in skeletal development and that regulation of BMP signaling is required for delineation of the various skeletal elements (Brunet et al., 1998; Capdevila and Johnson, 1998). As described herein, exogenously added noggin inhibits cartilage formation in micromass cultures. BMP-2 has been shown to stimulate the commitment and differentiation of pluripotent mesenchymal cells to the chondrocytic lineage (Ahrens et al., 1993; Wang et al., 1993). Thus, BMPs, especially -2/-4, are important in early skeletal development, and appear to have properties consistent with a functional importance in commitment and differentiation of mesenchymal cells to chondrocytes.

Overexpression of a caRAR α prevents prechondrogenic cell differentiation, even in the presence of BMP-2 or -4. Both BMP-2 and -4 enhance the expression of the prechondrogenic phenotype by stimulating the formation of numerous condensations as confirmed by magenta-gal staining and by in situ hybridization with probes for N-cadherin, gli-1, col-I and col-II. Nonetheless, neither BMP-2 nor BMP-4 was able to induce chondroblast differentiation of transgene-expressing cells. These results demonstrate that the regulation of RAR activity operates downstream of BMP-signaling in the chondroblast differentiation sequence. Additional evidence to suggest this comes from the observations that inhibition of cartilage formation by noggin can be circumvented by treatment of cultures with an RAR antagonist. During paraxial development, RAR α , RAR γ , are co-expressed in the condensing mesenchyme and in the perichondrium, which are both targets of BMP-2 and -4. Hence, these results suggest that during limb outgrowth BMP-2 and -4 are important in stimulating prechondrogenic cell condensation, whereas a loss of RAR α activity is important in allowing the differentiation of these cells. In this manner, the BMP and RA-signaling pathways may function sequentially in the commitment and differentiation of mesenchymal cells, respectively, during limb outgrowth.

RAR function in chondroblast differentiation: Conservation in other developmental processes

A similar hierarchy of BMP and RA signaling may be operating in other developmental processes. BMPs-2 and -4 and RARs are co-expressed in a number of different regions within the developing embryo. As mentioned previously, BMP-2 and -4 are co-expressed with RAR α , β , and γ in the interdigital region. Application of BMPs to the interdigital region enhances interdigital apoptosis (Macias et al., 1997; Yokouchi et al., 1996), while overexpression of a dominant-negative BMPRII inhibits interdigital apoptosis and webbed digits (Zou and Niswander, 1996; Zou et al., 1997). In addition, loss of RAR α , or loss of β and γ together, leads to a cessation of interdigital apoptosis and webbed digits. When cultured prior to the initiation of apoptosis, explants of the interdigital region will form cartilage unless RA is present in which case they will undergo apoptosis (Lee et al., 1994). Similarly, addition of RA to *in vitro* cultured limbs stimulates regression of the interdigital regions (Lussier et al., 1993). Together, these observations suggest that the BMPs and RA-signaling pathways coordinate interdigital cell death, in addition to chondrogenesis.

During heart formation BMP-2 and -4 appear to be important in specifying ventricular cardiomyocytes whereas the RARs regulate the differentiation of this population of cells. Loss of RAR activity through inactivation of RXR α , RXR β , RAR α causes precocious differentiation of ventricular myocytes (Kastner et al., 1997). Hence, RARs are functioning in the heart to regulate progenitor cell differentiation as they do within the limb.

One of the functions of RARs in limb development is to regulate the differentiation of skeletal progenitor cells. In this manner, RAR activity may specify the size of progenitor cell populations, and/or influence cell fate decisions by modulating the competency of cells to respond to inductive signals, such as BMPs. The status of cellular RAR activity, therefore, appears to be an important determinant in the spatiotemporal regulation of cell differentiation in the developing limb, heart and spinal cord.

RAR Antagonists

With the demonstration that RAR antagonist compounds can act as potent stimulators of chondrogenesis and associated skeletal development, various therapeutic *in vivo* and *in vitro* uses of such antagonists are now made possible

especially those uses involving abnormal chondrogenesis and related skeletal development.

The RAR antagonist AGN 194301, shown in Table 1, has been demonstrated to stimulate cartilage formation and promote chondroblast differentiation. AGN 194301 (2-Fluoro-4-[(1-(8-bromo-2,2-dimethyl-4-(4-methylphenyl)-2-*H*-chromen-6-yl)-methanoyl)-amino]-benzoic acid) is a potent antagonist of RAR α , with a high affinity for that receptor. It has a lower affinity for RAR β and RAR γ , but does also act as an antagonist of these receptors.

In accordance with one embodiment of the invention, chondrogenesis-stimulating RAR antagonists comprise antagonist compounds which are highly effective against RAR α and also antagonise RAR β and RAR γ . Thus, the present invention encompasses RAR antagonists in general and any agent which demonstrates RAR antagonist activity. Those of ordinary skill in the art are able to screen candidate compounds to identify compounds having such an RAR antagonist profile by methods available in the scientific literature, for example as described in Teng et al., (1997), J. Med. Chem., 40, 2445-2451.

In accordance with one embodiment of the invention, chondrogenesis-stimulating RAR antagonists comprise mono- or di-fluoro substituted methylchromenes such as AGN 194301. The RAR antagonist compounds of the invention may be synthesized by conventional chemical synthetic methods. For example, AGN 194301 may be synthesised as described in Teng et al., (*supra*). In some cases, suitable RAR antagonists may be purchased.

One skilled in the art would readily understand that several different types of RAR antagonists other than those described specifically herein are suitable for use in the present invention. Other suitable RAR antagonists are taught for example in WO 9933821, WO 9924415, U.S. 5,877,207 and JP 10114757. Such antagonist agents include but are not limited to AGN 193109, AGN 190121, AGN 194574, AGN 193174, AGN 193639, AGN 193676, AGN 193644, SRI 11335, Ro 41-5253, Ro 40-6055, CD 2366, BMS 185411, BMS 189453, CD-2665, CD 2019, CD 2781, CD 2665, CD 271. Other suitable RAR antagonists for use in the present invention include those disclosed in Kaneko et al., 1991; Apfel et al., 1992; Eyrolles et al., 1994; Yoshimura et al., 1995; Eckharat and Schmitt, 1994; and Teng et al., 1997.

The chondrogenesis-stimulating RAR antagonists of the invention are useful for the treatment and management of skeletal problems or abnormalities resulting from disease or trauma in vertebrates, including humans and other mammals, including horses. They may be used in several therapeutic applications where
5 increased chondrogenesis is desired and also for stimulation of skeletal development.

Therapeutic applications of these antagonists include the stimulation of new cartilage formation and accelerate associated bone repair through endochondral ossification.

A pharmaceutical composition comprising at least one chondrogenesis-
10 stimulating RAR antagonist may be applied locally to a fracture site, for example by means of a biodegradable sponge, gel, coating or paste. A suitable gel for use would be a collagen type gel such as collagen I.

The antagonists of the present invention may also be used for the treatment of orthopedic or dental implants to enhance or accelerate osseous integration. A
15 pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist may be directly applied locally to the site of desired osseous integration or alternatively as a coating on implants.

The RAR antagonists may also be used for promoting *in vivo* integration of implantable prosthetic devices. In general, the RAR antagonist compositions of the
20 invention may be applied to synthetic bone grafts for implantation whereby the antagonist composition stimulates cartilage formation and indirectly bone formation. The compositions thus have numerous applications in the orthopedic industry. In particular, there are applications in the fields of trauma repair, spinal fusion, reconstructive surgery, maxillo-facial surgery and dental surgery. The ability of the
25 RAR antagonist compositions to stimulate local natural bone growth provides stability and rapid integration, while the body's normal cell-based bone remodeling process slowly resorbs and replaces a selected implant with natural bone. Implants suitable for *in vivo* use are generally known to those skilled in the art.

The RAR antagonists of the invention may be used for cartilage and skeletal reconstruction. In such an application, the antagonists can be used for *ex vivo* tissue engineering of cartilage or skeletal tissue for implantation in a vertebrate. Cells can be treated with a RAR antagonist during osteochondral autograft or allograft transplants (Minas et al., (1997), Orthopedics, 20, 525-538). In autograft transplants, chondrogenic cells or cells with chondrogenic potential are removed from a patient (e.g. from a rib) and used to fill a cartilaginous lesion. An alternative method involves expanding these cells *in vitro*, then implanting them into a cartilaginous lesion. A pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist would be used to treat the cells in *in vitro* culture prior to engraftment and/or after engraftment through intra-articular injection. The use of the RAR compositions of the invention may eliminate the pain and costs associated with the bone harvest procedure required in autograft transplants. Furthermore, the RAR compositions can be made synthetically thus reducing the possibility of transmission of infection and disease, as well as diminishing the likelihood of immunological rejection by the patient.

The antagonist compositions of the present invention may also be used for the treatment of arthritis, either osteoarthritis or other types of arthritis including rheumatoid arthritis. To reverse or slow degenerative joint disease characterized by cartilage degeneration, a pharmaceutical composition comprising at least one chondrogenesis-stimulating RAR antagonist would be applied locally through intra-articular injection or in combination with a viscosupplement. The composition could be provided in either a fast-release or slow-release formulation. Such compositions have use in patients with degenerative hip or knee joints, for example.

In general, the RAR antagonists may be used to stimulate *in vitro* chondrogenesis from mesenchymal precursor cells and *in vitro* formation of chondrocytes. Such cell culture materials and methods are known to those skilled in the art and are also described herein in the examples. Cells and tissues treated with a selected RAR antagonist *in vitro* can be used therapeutically *in vivo* or alternatively for *in vitro* cellular assay systems.

The pharmaceutical compositions of the invention may be used in combination with other chondrogenic stimulators, e.g. bone morphogenetic proteins (BMPs)

especially BMP-2 and BMP-4, osteogenic proteins (OPs) such as OP-1 and/or cytokines to enhance and/or maintain the effects of the compositions. Both BMPs and OPs are proteins belonging to the TGF- β superfamily which represent proteins involved in growth and differentiation as well as tissue morphogenesis and repair. It is also understood that the RAR antagonist compositions of the invention may additionally comprise other chondroinductive agents or factors, defined as any natural or synthetic organic or inorganic chemical or biochemical compound, or mixture of compounds which stimulate chondrogenesis. It is further understood that the RAR antagonist compositions of the invention may also comprise other growth factors known to have a stimulatory effect on cartilage growth and formation.

The RAR antagonist compositions described herein appear to have a more dramatic effect on chondrocyte function than the BMPs and show longer-lived effects. The RAR antagonists are also more cost effective to manufacture than BMPs.

Those of ordinary skill in the art are familiar with various methods of formulating pharmaceutical compositions for local administration in diseases such as arthritis. For example, Adams et al., (1995), *Osteoarthritis & Cartilage*, 3, 213-225, describes viscosupplementation in osteoarthritis; Wozney et al., (1998), *Clin. Ortho. Rel. Res.*, 346, 26-37, describes delivery methods used for BMPs to effect bone repair and formation. These formulation methods may be employed to prepare the RAR compositions of the invention.

For therapeutic applications in accordance with the present invention the RAR antagonists are incorporated into pharmaceutical compositions formulated for oral or parenteral administration, the latter route including intravenous and subcutaneous administration. Parenteral administration may be by continuous infusion over a selected period of time. As such, the compositions may be provided as tablets, pills, capsules, solutions, suspensions, creams, gels, and the like.

An RAR antagonist may be orally administered with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, compressed into tablets or incorporated directly with the food of the diet. For oral therapeutic administration, the RAR antagonist may be incorporated with excipient and used in the form in ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

In one embodiment of the present invention, a pharmaceutical composition for administration to subjects in a biologically compatible form suitable for administration *in vivo* for treating abnormal chondrogenesis and associated skeletal development comprises a safe and effective amount of a selected RAR antagonist alone, or in combination with other agents and/or pharmaceutically acceptable carriers. The composition may be administered to any living organism including humans and animals. By "safe and effective amount" as used herein is meant providing sufficient potency in order to decrease, prevent, ameliorate or treat a chondrogenesis or skeletal disorder affecting a subject while avoiding serious side effects. A safe and effective amount will vary depending on the age of the subject, the physical condition of the subject being treated, the severity of the disorder, the duration of treatment and the nature of any concurrent therapy. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The compositions are preferably in the form of a unit dose and will usually be administered as a dose regimen that depends on the particular tissue treatment.

The compositions described herein can be prepared by known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable carrier. By pharmaceutically acceptable carrier as used herein is meant one or more compatible conventional solid or liquid delivery systems as are well known in the art. Some examples of pharmaceutically acceptable carriers are sugars, starches, cellulose and its derivatives, powdered tragacanth, malt, gelatin, collagen, talc, stearic acids, magnesium stearate, calcium sulfate, vegetable oils, polyols, agar, alginic acids, pyrogen-free water, isotonic saline, phosphate buffer, and other suitable non-toxic substances and medicinal agents used in pharmaceutical formulations. Other excipients such as wetting agents and lubricants, tableting agents, stabilizers, anti-oxidants and preservatives are also contemplated. Suitable carriers are further described for example in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis the compositions include, albeit not

exclusively, solutions of the substance in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The RAR antagonist compositions of the invention can be provided as a liquid for local administration at a desired tissue site such as by injection. Alternatively, the compositions of the invention can be provided encapsulated for administration to a desired tissue site. In one embodiment, the RAR antagonist composition may comprise at least one RAR antagonist which may be provided as a solution or emulsion contained within phospholipid vesicles called liposomes. The liposomes may be unilamellar or multilamellar and are formed of constituents selected from phosphatidylcholine, dipalmitoylphosphatidylcholine, cholesterol, phosphatidylethanolamine, phosphatidylserine, demyristoylphosphatidylcholine and combinations thereof. The multilamellar liposomes comprise multilamellar vesicles of similar composition to unilamellar vesicles, but are prepared so as to result in a plurality of compartments in which the silver component in solution or emulsion is entrapped. Additionally, other adjuvants and modifiers may be included in the liposomal formulation such as polyethyleneglycol, or other materials.

It is understood by those skilled in the art that any number of liposome bilayer compositions can be used in the composition of the present invention. Liposomes may be prepared by a variety of known methods such as those disclosed in U.S. Patent No. 4,235,871 and in RRC, Liposomes: A Practical Approach. IRL Press, Oxford, 1990, pages 33-101.

The liposomes containing the RAR antagonist may have modifications such as having non-polymer molecules bound to the exterior of the liposome such as haptens, enzymes, antibodies or antibody fragments, cytokines and hormones and other small proteins, polypeptides or non-protein molecules which confer a desired enzymatic or surface recognition feature to the liposome. Surface molecules which preferentially target the liposome to specific organs or cell types include for example antibodies which target the liposomes to cells bearing specific antigens. Techniques for coupling such molecules are well known to those skilled in the art (see for example U.S. Patent 4,762,915 the disclosure of which is incorporated herein by reference). Alternatively, or in conjunction, one skilled in the art would understand that any number of lipids

bearing a positive or negative net charge may be used to alter the surface charge or surface charge density of the liposome membrane.

The liposomes can also incorporate thermal sensitive or pH sensitive lipids as a component of the lipid bilayer to provide controlled degradation of the lipid vesicle
5 membrane.

For systemic application by intravenous delivery, it may be beneficial to encapsulate the RAR antagonist within sterically-stabilized liposomes which exhibit prolonged circulation time in blood. The sterically stabilized liposomes are produced containing polyethylene glycol as an essential component of their surface and the
10 method of making such liposomes is known to those skilled in the art.

The size of the liposomes can be selected based on the intended target and route of administration. Liposomes of between about 10 nm to 300 nm may be suitable. Furthermore, the composition of the present invention may include liposomes of different sizes.

15 While the composition of the present invention may be encapsulated for administration by liposomes, it is understood by those skilled in the art that other types of encapsulants may also be used to encapsulate the RAR antagonist. Microspheres including but not limited to those composed of ion-exchange resins, crystalline ceramics, biocompatible glass, latex and dispersed particles are suitable for
20 use in the present invention. Similarly, nanospheres and other lipid, polymer or protein materials can also be used.

The RAR antagonist compositions of the present invention may comprise a RAR antagonist dispersed in an implantable biocompatible carrier that functions as a suitable delivery or support system for the antagonist. Suitable examples of
25 biocompatible sustained release carriers include semi-permeable polymer matrices in the form of shaped implantable articles such as polylactides, copolymers of L-glutamic acid, ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate) or ethylene vinyl acetate. Such matrices can be fabricated to have the RAR antagonist incorporated therein and be of a selected pore size to permit chondroprogenitor cells and skeletal
30 progenitor cells to migrate within. The selected carrier material may also comprise a biodegradable, synthetic or synthetic-organic matrix such as hydroxyapatite, collagen, tricalcium phosphate or various copolymers of glycolid, lactic and butyric acid.

The RAR antagonist composition of the present invention may also be used with demineralized allogenic bone and demineralized xenogenic bone optionally treated with fibril modifying agents. Furthermore, the composition may be provided with a mechanical or suitable physical device, influence or force such that it functions to promote chondrogenesis and skeletal development either *in vitro* or *in vivo*.

In summary, RAR antagonists have important clinical therapeutic uses for treatment of cartilage and associated bone development defects. The RAR antagonists can be used to provide such treatment both *in vitro* and *in vivo* to treat a variety of conditions as a result of trauma, genetic disease or degenerative disease negatively affecting cartilage and associated bone development and maintenance.

EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.

Methods of chemistry, protein and peptide biochemistry, cell biology, molecular biology and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

Methods

Preparation of micromass cultures

Micromass cultures were prepared from murine E11.25 to E11.75 fore and hind limb buds as previously described with the following modifications (Cash et al., 1997). After proteolytic digestion cells were filtered through a Cell Sieve (40 μ M, Falcon) to obtain a single cell suspension. Culture media (40% Dulbecco's modified Eagle's medium, 60% F12 was supplemented with fetal bovine serum to 10%, Gibco-BRL) was changed daily. BMP-2 or-4 (Genetics Institutes), AGN 194301 (Allergan Pharmaceuticals) and/or purified *Xenopus* noggin protein was added to culture media at a concentration of 10ng/ml, 1 μ M and 10ng/ml, respectively. Addition/removal experiments included either adding or removing supplemented media on the indicated culture day, 24 hours after culture initiation was considered day 1. To detect transgene-expressing cells, cultures were fixed stained as previously described, with

magenta-gal (BioSynth International Inc.) being substituted for X-gal. This was followed by alcian blue staining for cartilage-specific glycosaminoglycans. Alcian blue staining of magenta-gal stained cultures turned the red precipitate to a purple color, this is a result of incubating magenta-gal stained cells at pH 1. This double-staining technique enables transgene-expressing cells to be localized with respect to alcian blue stained cartilage nodules.

Synthesis of Riboprobes

Riboprobes were synthesized in the presence of UTP-digoxigenin with the appropriate RNA polymerase and linearized template DNA according to the manufacturers directions (Boehringer Mannheim Corp., Indianapolis, IN). Riboprobe complementary to collagen type II gene, was generated from Bam H1 linearized pBluescript containing 1.1kb of the collagen type II gene containing the C-propeptide and transcribed *in vitro* with T7 RNA polymerase. Gli-1 riboprobe was transcribed from Not I linearized pBluescript containing a 1.6 kb fragment representing most of the zinc finger domain of gli-1. A 553 bp fragment of murine collagen type I (Phillips et al., 1992) was subcloned into pKS II (Stratagene), this was linearized with XhoI and transcribed with T7 RNA polymerase. A Hind III (position 605) -BamH1 (position 1252) fragment from the mouse N-cadherin cDNA was subcloned into pKSII. This construct was linearized with Bam H1 and riboprobe synthesized with T7 RNA polymerase. For controls, sense riboprobes were synthesized from the aforementioned plasmids.

Whole-Mount *In situ* Hybridization of Micromass Cultures

In situ hybridizations were carried out on micromass cultures using a technique described previously (Cash et al., 1997), with minor modifications. After permeabilization using 10 µg/ml proteinase-K in phosphate buffered saline (PBS) supplemented with 0.05% Triton X-100, cells were post-fixed in 4% paraformaldehyde and 2% glutaraldehyde in PBS and hybridizations were carried out at 60°C instead of 55°C.

Transient Transfection Analysis

The ability of AGN194301 to inhibit all-trans RA induction of an RARE containing luciferase construct was performed in P19 embryonal carcinoma cells as previously described with some modification (Underhill et al., 1994). P19 cells were seeded at a density of 1.5×10^4 cells/well in 6 well plates. Cells were transfected using the calcium phosphate precipitation method with each well receiving 3.9 μg DNA (1.25 μg pW1RAREtk-lucif, 0.33 μg pW1ActRAR α / β / γ , .67 μg pW1Act β -galactosidase and 1.65 μg pGEM9zf(-)). Following transfection cells were washed and fresh media was added that contained 1×10^{-7} M all-trans RA and various amounts of AGN194301. Twenty-four hours later cell extracts were prepared, and luciferase and β -galactosidase activity measured. Luciferase activity was normalized with β -galactosidase activity to control for differences in transfection efficiency.

Northern Blot Analysis

Total RNA was isolated dissected and pooled limb buds from wild-type and transgenic embryos at various gestational stages with TriPure Isolation Reagent (Boehringer Mannheim). RNA samples were separated by electrophoresis of 15 μg aliquots in a 1% agarose-formaldehyde gel. RNA was then transferred to a Hybond-N nylon membrane (Amersham Life Science) and cross-linked by UV irradiation. Blots were pre-hybridized in Church's Buffer (7% SDS, 0.5 M NaPi pH 7.2, 1mM EDTA, 1% BSA) at 65 $^{\circ}$ C for at least 30 min. Radiolabeled DNA probes were synthesized by random priming using standard methods with the appropriate cDNA insert fragments. Hybridizations were carried out overnight at 60 $^{\circ}$ C. Following hybridization blots were washed with wash buffer (250mM NaPi, 10% SDS) three times for 15 min. at 65 $^{\circ}$ C, and exposed to BioMax X-ray film at -80 $^{\circ}$ C for 1-4 days.

Example 1: Transgene-expressing cells do not contribute to cartilage nodule formation

To further demonstrate the role of the RARs, specifically RAR α , during cartilage formation, we used a previously described transgenic mouse model (Cash et al., 1997). Overexpression of a weak constitutively active RAR α during limb development leads to various congenital malformations of the limb that are

reminiscent of those observed in RA teratogenicity. During chondroblast differentiation, RAR α expression is down-regulated. The continued expression of RAR α inhibits chondroblast differentiation leading to a cessation of cartilage formation and to skeletal deficiencies as observed in the transgenic mice. Limb mesenchyme from embryonic age (E) 11.5 transgenic embryos was used to set up micromass cultures to examine the cell fate of transgene-expressing cells during *in vitro* chondrogenesis. Shown in figure 1 is a time-course of cartilage nodule formation (day-2, day-4 and day-6) in wild-type (figure 1A, B, and C) and transgenic fore limb cultures (figure 1E, 1F, 1G) and hind limb cultures (figure 1H, day-4 shown). Consistent with previous observations there are many fewer alcian blue-stained nodules in the transgenic derived cultures than in the wild-type cultures. Using a combination of magenta-gal and alcian blue staining, we clearly show that transgene-expressing cells are, for the most part, excluded from the cartilage nodules (figure 1D) but appear to form condensations. Transgene-expressing cells fail to differentiate into chondroblasts in contrast to both non-transgene-expressing cells within the same cultures, and cells within wild-type cultures.

Example 2: Transgene-expressing cells have a prechondrogenic phenotype

Cartilage formation involves two well described steps: 1) condensation of mesenchymal cells; 2) differentiation of condensed mesenchyme to matrix-producing chondrocytes (Hall and Miyake, 1992). These two stages can be distinguished based on histological staining, however, using molecular markers is generally a more reliable method for determining the phenotype of cells at either stage. Previous studies have shown that condensed prechondrogenic cells express col II weakly and express N-cad, col I and gli-1 abundantly (Hall and Miyake, 1995; Marigo et al., 1996; Oberlender and Tuan, 1994). Upon differentiation of these cells, col II expression becomes much stronger, whereas expression of N-cad, col I, and gli-1 are downregulated. To further characterize the phenotype of the transgene-expressing cells, whole mount *in situ* hybridization was carried out to examine the expression patterns of col II, N-cad, col I and gli-1 in transgenic and wild-type cultures. In wild-type cultures, col II expression was very strong and localized primarily to the core of the cartilage nodules with weaker expression in regions surrounding the

nodules (figure 2A). Expression of N-cad, col I and gli-1 in wild-type cultures was restricted to perinodular regions in condensed mesenchyme and was weakly expressed in the centre of the nodules (figure 2C, E and G). The expression patterns of these genes in the wild-type cultures is consistent with their expression *in vivo*. In
5 transgenic cultures, however, their expression patterns would indicate that while condensations are present the condensed cells have not yet differentiated. There was no downregulation of N-cad, col I or gli-1, instead they were expressed throughout the condensations (figure 2D, F and H), whereas col II was only weakly expressed (figure 2B), resembling a pattern one would expect to see in condensations but not in
10 cartilage nodules. These observations demonstrate that the transgene-expressing cells condense but do not undergo chondroblast differentiation.

Comparison of the distribution of col II expression in transgenic and wild-type cultures suggests that the transgenic cultures form a similar number of condensations as observed in wild-type cultures (figure 2A, B). Furthermore, the col II stained
15 regions in transgenic and wild-type cultures are similar in size indicating that transgene-mediated inhibition of chondroblast differentiation was not a consequence of insufficient numbers of prechondrogenic cells (Hall and Miyake, 1992). Moreover, during the culture period the transgene-expressing cell aggregates continue to expand in size and staining intensity (figure 1E, 1F and 1G). Northern blot analysis has
20 confirmed differential expression of col II and gli-1 between the hind limbs of wild-type and transgenic mice. By E 14.5, col II is downregulated in transgenic hind limbs (Figure 2I), whereas gli-1 is downregulated in transgenic hind limb at E 12.5 (Figure 2I). The *in situ* hybridization results combined with results from Northern blot analysis demonstrate that the phenotype displayed by transgene-expressing cells is
25 consistent with condensed prechondrogenic cells.

Example 3: Transgene-expressing cells are refractile to BMP-stimulated chondroblast differentiation

To further investigate the mechanism of transgene-mediated inhibition of
30 chondroblast differentiation, the expression of genes known to be important in chondrogenesis, namely the BMPs was examined. Based on their expression in limb development and their well defined chondrogenic stimulatory properties, the analysis

was focused on *bmps-2* and *-4*. Hence, one plausible explanation for the transgenic phenotype was either the reduced expression of *bmps* or overexpression of *noggin* which encodes an inhibitor of BMP signaling. Northern analysis using mRNA from hind limbs of transgenic and wild-type animals at E 11.5, 12.5, and E 14.5 demonstrated that neither *bmp2* nor *noggin* is differentially expressed in transgenic animals in comparison to wild-type animals (data not shown). The defect in transgenic limb mesenchyme therefore is not likely a result of changes in expression of either of these two transcripts. However, these results do not preclude the possibility that transgene-expressing mesenchymal cells are unresponsive to BMPs.

To evaluate whether transgene-expressing cells are able to respond to BMPs, transgenic and wild-type micromass cultures were treated with 10 ng/ml BMP-2 and -4. It was demonstrated that addition of BMP-2 (figure 3A) and -4 dramatically increases the number of cartilage nodules in wild-type and transgenic cultures. BMP-2 treatment for six days increased the number of cartilage nodules by ~125% and ~115% in wild-type and transgenic fore limb cultures, respectively (figure 3A-I). Hence, addition of BMP-2 or -4 appears to rescue the chondrogenic defect present in transgenic cultures. To confirm this, BMP-2 treated cultures were stained with magenta-gal followed by alcian blue (figure 3F, G and H). As observed in non-treated transgenic cultures, few if any transgene-expressing cells were found to be present within the alcian blue stained cartilage nodules (figure 3I). Addition of BMP-2, however, stimulated condensation of transgene-expressing cells (figure 3F-I). This was confirmed by *in situ* hybridization, BMP-2 addition stimulated the formation of col II expressing nodules and weak col II condensations in wild-type and transgenic cultures, respectively (Figure 4). Condensations were observed as early as 2 days in culture and were still evident after 6 days in culture. Thus, although BMP-2 or -4 induces transgene-expressing cells to form precartilaginous condensations they are not sufficient to overcome transgene-mediated inhibition of prechondrogenic cell differentiation.

Example 4: Loss of retinoic acid receptor activity stimulates chondrogenesis

It has presently been demonstrated that the continued expression of RAR α inhibits the transition of prechondrogenic cells to chondroblasts. It was then

demonstrated that the abrogation of RAR α activity stimulated chondroblast differentiation and/or cartilage formation. RAR activity as used herein refers to the level of RA-induced transcriptional activity of the RARs. Micromass cultures were treated with the RAR α -specific antagonist AGN194301 to examine whether

5 inhibition of RAR α activity stimulated cartilage formation. Addition of 1 μ M AGN194301 to wild-type micromass cultures lead to a dramatic increase in nodule number with no apparent increase in nodule size as compared to untreated control cultures (figure 5G, J, M). After 8 days in culture there were 60% more nodules in antagonist treated cultures than in untreated cultures (figure 5M). Similar to the

10 inhibition of cartilage nodule formation observed in response to all-trans RA treatment of micromass cultures, addition of the RAR α -specific agonist AGN 193836 at 1 μ M, decreased the number of cartilage nodules that formed by 35% with the nodules staining only weakly with alcian blue. To confirm that the concentrations utilized in these experiments inhibited RAR α activity specifically, the level of RAR α ,

15 RAR β and RAR γ mediated RARE activation was measured with 100nM all-trans RA in the presence of various concentrations of antagonist. At 1 μ M of AGN194301, RAR α signaling was inhibited to ~0.3% of controls, while RAR β and RAR γ were inhibited to ~18% and ~26% of controls, respectively. Hence, most of the chondrogenic stimulatory properties of the antagonist appear to be mediated through

20 inhibition of RAR α , however, it cannot be entirely discounted that diminution of RAR β or RAR γ signaling may have contributed to these results. Nonetheless, loss of RAR activity stimulates cartilage formation while increased RAR activity inhibits cartilage formation.

25 **Example 5: The RAR antagonist and BMP-2 have different chondrogenic stimulatory properties**

The loss of RAR activity and addition of BMP-2 both stimulate cartilage formation. In transgenic cultures, BMP-2 stimulated condensation but not differentiation of transgene-expressing cells, whereas a loss of RAR α activity induced

30 cartilage formation. These results suggest that the two factors: a) BMP-2 availability and b) RAR α activity are important at different stages during chondrogenesis. To

further delineate the role of BMP-2 and RAR α in cartilage formation, we have used an approach that involves incubation of micromass cultures with AGN194301 or BMP-2 for different periods of time during culturing. To accomplish this BMP-2 or AGN194301 were added to cultures for the first 2 or 3 days then removed, or were
5 added after 2 or 3 days of culturing. As has been shown previously (Roark and Greer, 1994), addition of BMP-2 at later culture periods yielded results that are comparable to experiments in which BMP-2 is added continuously from the start of culture (figure 5D-F). Conversely, addition of BMP-2 for the first 2 to 3 days of culture caused an increase in nodule number but this increase was not as dramatic as that observed upon
10 adding BMP-2 later (ie: after 2 or 3 days). The average size of the nodules was also noticeably increased in cultures that were either continuously exposed to BMP-2 or treated after 2 or 3 days of culture (figure 5B-F). These large nodules radiate towards the outside of the culture and are, in part, a consequence of the recruitment of proliferating uncommitted cells present in the periphery of the culture into the
15 nodules. Similar observations have been made with BMP-2 addition *in vivo* as Duprez *et al.* (Duprez *et al.*, 1996) showed that expansion of skeletal elements in the presence of BMP-2 or -4 was at the expense of other cell populations in the developing chick limb bud. Hence, the consequences of BMP-2 addition are much more pronounced in cultures treated at later stages of culture and likely reflect the
20 ability of BMP-2 to stimulate commitment of mesenchymal cells to the chondrocytic lineage with subsequent recruitment into nodules.

In contrast to BMP-2 and -4, AGN194301 had its most pronounced stimulatory effect on nodule formation when it was present early in the culture period. When 1 μ M AGN194301 was added to cultures for only the first 2 or 3 days, then
25 removed, more cartilage nodules were formed compared to untreated cultures (figure 5G-I) or to cultures exposed for longer periods of time but untreated for the first 2 or 3 days (figure 5K, L). Interestingly, the increase in nodule number caused by early treatment of the antagonist was maintained for 4 or more days after its removal and was comparable to the increase in nodule number observed with continuous treatment
30 (figure 5H-J). AGN194301, therefore, caused an increase in nodule formation, however the nodules were much smaller compared to cultures receiving antagonist at later culture times. When BMP-2 and AGN194301 were added together to

micromass cultures at a concentration of 10ng/ml and 1 μ M, respectively, there was a ~100% increase in nodule number compared to untreated controls (figure 5M). BMP-2 addition alone to cultures initiated from the same limb buds caused a ~45% increase, whereas AGN194301 treatment caused an increase of ~60% (figure 5M).

5 Together, these results demonstrate that the loss of RAR activity and the presence of a BMP signal are two events that act at different stages of the chondrogenic sequence as they exhibit markedly different chondrogenic stimulatory properties.

**Example 6: Cartilage formation is rescued in Noggin-treated cultures by
10 addition of an RAR α antagonist**

To further address the requirement for BMPs in chondrogenesis, wild-type limb mesenchyme cultures were treated with Noggin, a secreted inhibitor of BMP-2, and -4. Addition of 10ng/ml Noggin to wild-type cultures dramatically reduced cartilage nodule formation by ~84% in comparison to untreated controls (Fig 6a, b
15 and d). In an attempt to define the chondrogenic stage affected by Noggin, cultures treated with Noggin were examined for the expression of *col II* and *col IIA* an alternatively spliced form of col II expressed in prechondrogenic cells (Sandell, et al., 1991, Sandell, et al., 1994). In limb bud derived cultures *col IIA* is expressed in the condensing mesenchyme surrounding cartilaginous nodules and in precartilaginous
20 condensations (Fig. 6e, f). If Noggin delays or inhibits chondroblast differentiation but does not affect condensation, then the decrease in col II expressing nodules should be accounted for by col IIA expressing condensations. In contrast, however, comparison of expression of these two genes by *in situ* hybridization in Noggin-treated cultures indicates there are no additional condensations present (Fig. 6e, f).
25 Hence, Noggin appears to interfere with formation of precartilaginous condensations.

Earlier experiments in which addition of BMP-2 was unable to rescue cartilage in transgene-expressing cultures coupled with the accelerated appearance of col II expressing cells in antagonist-treated cultures demonstrated that loss of RAR activity alone is sufficient to initiate the chondrogenic differentiation program. To
30 further demonstrate this, Noggin-treated cultures were exposed to the RAR antagonist. The addition of 1 μ M AGN194301 to Noggin-treated cultures, stimulated cartilage nodule formation such that these cultures resembled untreated cultures

(figure 6a, c and d). In contrast, addition of 10 or 20 nM all-trans RA further diminished nodule formation in Noggin-treated cultures (data not shown). These results indicate that suppression of RAR-mediated signaling not only stimulates expression of the chondrogenic phenotype, but can do so independently of a BMP
5 signal.

References

- Adams, M. E., Atkinson, M. H., Lussier, A. J., Schulz, J. I., Siminovitch, K. A.,
Wade, J. P., and Zumner, M. (1995). The role of viscosupplementation with hylan G-
F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter
5 trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-
inflammatory drugs (NSAIDs) and NSAIDs alone. *Osteoarthritis & Cartilage* 3, 213-
25.
- 10 Ahrens, M., Ankenbauer, T., Schroder, D., Hollnagel, A., Mayer, H., and Gross, G.
(1993). Expression of human bone morphogenetic proteins-2 or -4 in murine
mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct
mesenchymal cell lineages. *DNA Cell Biol.* 12, 871-880.
- 15 Amos, B., and Lotan, R. (1990). Retinoid-sensitive cells and cell lines. *Meth. Enz.*
190, 217-225.
- Apfel, C. et al. (1992). Retinoic Acid Receptor alpha Antagonist Selectivity
Counteracts Retinoic Acid Effects. *Proc. Natl. Acad. Sci. U.S.A.* 89, 7129-7133.
- 20 Brunet, L. J., McMahon, J. A., McMahon, A. P., and Harland, R. M. (1998). Noggin,
cartilage morphogenesis, and joint formation in the mammalian skeleton [see
comments]. *Science* 280, 1455-7.
- 25 Capdevila, J., and Johnson, R. L. (1998). Endogenous and ectopic expression of
noggin suggests a conserved mechanism for regulation of BMP function during limb
and somite patterning. *Dev Biol* 197, 205-17.
- Cash, D. E., Bock, C., Schughart, K., Linney, E., and Underhill, T. M. (1997).
30 Retinoic acid receptor alpha function in vertebrate limb skeletogenesis: a modulator
of chondrogenesis. *J. Cell Biol.* 136, 445-457.

Chambon, P. (1996). A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954.

5 Dolle, P., Ruberte, E., Kastner, P., Petkovich, M., Stoner, C. M., Gudas, L. J., and Chambon, P. (1989). Differential expression of genes encoding alpha, beta and gamma retinoic acid receptors and CRABP in the developing limbs of the mouse. Nature 342, 702-705.

10 Duke, J., and Elmer, W. A. (1977). Effect of the brachypod mutation on cell adhesion and chondrogenesis in aggregates of mouse limb mesenchyme. J. Embryol. Exp. Morph. 42, 209-217.

Duprez, D., de H. Bell. E. J., Richardson, M. K., Archer, C. W., Wolpert, L., Brickell, P. M., and Francis-West, P. H. (1996). Overexpression of BMP-2 and BMP-4 alters
15 the size and shape of developing skeletal elements in the chick limb. Mechanisms of Development 57, 145-157.

Duprez, D. M., Coltey, M., Amthor, H., Brickell, P. M., and Tickle, C. (1996). Bone Morphogenetic Protein-2 (BMP-2) inhibits muscle development and promotes
20 cartilage formation in chick limb bud cultures. Developmental Biology 174, 448-452.

Eckhardt, K., and Schmitt, G. (1994). A retinoic receptor alpha antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malformations in vivo. Toxicol. Lett. 70, 299-308
25

Ede, D. (1983). Cellular condensations and chondrogenesis. In Cartilage: Development, Differentiation and Growth, B. K. Hall, ed. (New York: Academic Press), pp. 143-185.

30 Eyrolles, L. et al. (1994). Retinoid Antagonists with a Heterocyclic Ring. J. Med. Chem. 37, 1508-1517.

Ghyselinck, N. B., Dupe, V., Dierich, A., Messaddeq, N., Garnier, J. M., Rochettegly, C., Chambon, P., and Mark, M. (1997). Role of the Retinoic Acid Receptor Beta (RAR-Beta) During Mouse Development. *Int. J. Dev. Biol.* 41, 425-447.

5

Hall, B. K., and Miyake, T. (1995). Divide, accumulate, differentiate: cell condensation in skeletal development revisited. *Int. J. Dev. Biol.* 39, 881-893.

Hall, B. K., and Miyake, T. (1992). The membranous skeleton: The role of cell
10 condensations in vertebrate skeletogenesis. *Anat. Embryol.* 186, 107-124.

Hogan, B. L. (1996). Bone morphogenetic proteins in development. *Current opinion in genetics and development* 6, 432-438.

15 Jones, C. M., Lyons, K. M., and Hogan, B. L. M. (1991). Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. *Development* 111, 531-542.

Kaneko, S. et al. (1991). Retinoid Antagonists. *Med. Chem. Res.* 1, 220-225.

20

Kastner, P., Messaddeq, N., Mark, M., Wendling, O., Grondona, J. M., Ward, S., Ghyselinck, N., and Chambon, P. (1997). Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes. *Development* 124, 4749-58.

25

Kingsley, D. M. (1994). The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. *Genes & Dev.* 8, 133-146.

Kingsley, D. M., Bland, A. E., Grubber, J. M., Marker, P. C., Russell, L. B.,
30 Copeland, N. G., and Jenkins, N. A. (1992). The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF-beta superfamily. *Cell* 71, 399-410.

Kistler, A. (1987). Limb bud cell cultures for estimating the teratogenic potential of compounds. *Arch. Toxicol.* 60, 403-414.

- 5 Kochhar, D. M. (1973). Limb development in mouse embryos. I. Analysis of teratogenic effects of retinoic acid. *Teratology* 7, 289-295.

Kochhar, D. M., and Aydelotte, M. B. (1974). Susceptible stages and abnormal morphogenesis in the developing mouse limb, analysed in organ culture after
10 transplacental exposure to vitamin A (retinoic acid). *J. Embryol. Exp. Morph.* 31, 721-734.

Kochhar, D. M., Jiang, H., Penner, J. D., Johnson, A. T., and Chandraratna, R. A. S. (1998). The use of a retinoid receptor antagonist in a new model to study vitamin a-
15 dependent developmental events. *Int. J. Dev. Biol.* 42, 601-608.

Kwasigroch, T. E., and Kochhar, D. M. (1980). Production of congenital limb defects with retinoic acid: phenomenological evidence of progressive differentiation during limb morphogenesis. *Anat. Embryol.* 161, 105-113.

20 Lee, K. H., Li, F. C. H., Yung, W. T., Kung, J. L. S., Ng, J. N., and Cheah, K. S. E. (1994). Influence of digits, ectoderm, and retinoic acid on chondrogenesis by mouse interdigital mesoderm in culture. *Dev. Dynam.* 201, 297-309.

25 Lohnes, D., Kastner, P., Dierich, A., Mark, M., LeMeur, M., and Chambon, P. (1993). Function of retinoic acid receptor gamma in the mouse. *Cell* 73, 643-658.

Lohnes, D., Mark, M., Mendelsohn, C., Dolle, P., Dierich, A., Gorry, P., Gansmuller, A., and Chambon, P. (1994). Function of the retinoic acid receptors (RARs) during
30 development (I) Craniofacial and skeletal abnormalities in RAR double mutants. *Development* 120, 2723-2748.

- Lufkin, T., Lohnes, D., Mark, M., Dierich, A., Gorry, P., Gaub, M.-P., LeMeur, M., and Chambon, P. (1993). High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. *Proc. Natl. Acad. Sci. USA* 90, 7225-7229.
- 5 Luo, G., Hofmann, C., Bronckers, A. L. J. J., Sohocki, M., Bradley, A., and Karsenty, G. (1995). BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. *Genes & Dev.* 9, 2808-2820.
- 10 Luo, J., Pasceri, P., Conlon, R. A., Rossant, J., and Giguere, V. (1995). Mice lacking all isoforms of retinoic acid receptor beta develop normally and are susceptible to the teratogenic effects of retinoic acid. *Mech. Dev.* 53, 61-71.
- Lussier, M., Canoun, C., Ma, C., Sank, A., and Shuler, C. (1993). Interdigital soft tissue separation induced by retinoic acid in mouse limbs cultured in vitro. *Int. J. Dev. Biol.* 37, 555-564.
- 15 20 Lyons, K. M., Pelton, R. W., and Hogan, B. L. M. (1990). Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for Bone Morphogenetic Protein-2A (BMP-2A). *Development* 109, 833-844.
- Macias, D., Ganan, Y., Sampath, T. K., Piedra, M. E., Ros, M. a., and Hurle, J. M. (1997). Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. *Development* 124, 1109-1117.
- 25 Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994). The retinoid receptors. In *The Retinoids: Biology, Chemistry, and Medicine*, M. B. Sporn, A. B. Roberts and D. S. Goodman, eds. (New York: Raven Press Ltd.), pp. 319-349.
- 30 Marigo, V., Johnson, R. L., Vortkamp, A., and Tabin, C. J. (1996). Sonic hedgehog differentially regulates expression of GLI and GLI3 during limb development. *Dev. Biol.* 180, 273-283.

- McBurney, M. W., Jones-Villeneuve, E. M. V., Edwards, M. K. S., and Anderson, P. J. (1982). Control of muscle and neuronal differentiation in cultured embryonal carcinoma cell line. *Nature* 299, 165-167.
- 5 Mendelsohn, C., Ruberte, E., LeMeur, M., Morriss-Kay, G., and Chambon, P. (1991). Developmental analysis of the retinoic acid-inducible RAR-beta2 promoter in transgenic animals. *Development* 113, 723-734.
- Minas, T., and Nehrer, S. (1997). Current concepts in the treatment of articular
10 cartilage defects. *Orthopedics* 20, 525-538.
- Moses, H. L., and Serra, R. (1996). Regulation of differentiation by TGF-beta. *Current opinion in genetics and development* 6, 581-586.
- 15 Oberlender, S. A., and Tuan, R. S. (1994). Spatiotemporal profile of N-cadherin expression in the developing limb mesenchyme. *Cell Adhes Commun* 2, 521-37.
- Paulsen, D. F., Chen, W.-D., Okello, D., and Johnson, B. (1994a). Stage- and region-dependent responses of chick wing bud mesenchymal cells to retinoic acid in serum-
20 free microcultures. *Dev. Dynam.* 201, 310-323.
- Paulsen, D. F., Solursh, M., Langille, R. M., Pang, L., and Chen, W.-D. (1994). Stable, position-related responses to retinoic acid by chick limb-bud mesenchymal cells in serum-free cultures. *In Vitro Cell. Dev. Biol.* 30A, 181-186.
- 25 Phillips, C. L., Morgan, A. L., Lever, L. W., and Wenstrup, R. J. (1992). Sequence analysis of a full-length cDNA for the murine Proa2(I) collagen chain: Comparison of the derived primary structure with human Proa2(I) collagen. *Genomics* 13, 1345-1346.

Roark, E. F., and Greer, K. (1994). Transforming growth factor-b and bone morphogenetic protein-2 act by distinct mechanisms to promote chick limb cartilage differentiation in vitro. *Dev. Dynam.* 200, 103-116.

- 5 Rosen, V., Thies, R. S., and Lyons, K. (1996). Signaling pathways in skeletal formation: A role for BMP receptors. *Annals of the New York Academy of Science* 785, 59-69.

- 10 Rosen, V., Wozney, J. M., Wang, E. A., Cordes, P., Celeste, A., McQuaid, D., and Kurtzberg, L. (1989). Purification and molecular cloning of a novel group of BMPs and localization of BMP mRNA in developing bone. *Connect Tissue Res* 20, 313-9.

- Ruberte, E., Dolle, P., Krust, A., Zelent, A., Morriss-Kay, G., and Chambon, P. (1990). Specific spatial and temporal distribution of retinoic acid receptor gamma transcripts during mouse embryogenesis. *Development* 108, 213-222.
- 15

Shenefelt, R. E. (1972). Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. *Teratology* 5, 103-118.

- 20 Solloway, M. J., Dudley, A. T., Bikoff, E. K., Lyons, K. M., Hogan, B. L., and Robertson, E. J. (1998). Mice lacking Bmp6 function. *Dev Genet* 22, 321-39.

- Storm, E. E., Huynh, T. V., Copeland, N. G., Jenkins, N. A., Kingsley, D. M., and Lee, S.-J. (1994). Limb alterations in brachypodism mice due to mutations in a new member of the TGFb-superfamily. *Nature* 368, 639-643.
- 25

Teng, M., Duong, T. T., Johnson, A. T., Klein, E. S., Wang, L., Khalifa, B., and Chandraratna, R. A. S. (1997). Identification of highly potent retinoic acid receptor alpha-selective antagonists. *J. Med. Chem.* 40, 2445-2451.

Underhill, T. M., Cash, D. E., and Linney, E. (1994). Constitutively active retinoid receptors exhibit interfamilial and intrafamilial promoter specificity. *Mol. Endo.* 8, 274-285.

- 5 Underhill, T. M., and Weston, A. D. (1998). Retinoids and their receptors in skeletal development. *Micro. Res. Tech.* 43, 137-155

Wang, E. A., Isreal, D. I., Kelly, S., and Luxenberg, D. P. (1993). Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and
10 3T3 cells. *Growth factors* 9, 57-71.

Winnier, G., Blessing, M., Labosky, P. A., and Hogan, B. L. M. (1995). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes & Dev.* 9, 2105-2116.

- 15 Wolpert, L. (1990). Signals in limb development: STOP, GO, STAY and POSITION. *J. Cell Sci. Suppl.* 13, 199-208.

Wozney, J. M., and Rosen, V. (1998). Bone morphogenetic protein and bone
20 morphogenetic protein gene family in bone formation and repair. *Clin. Ortho. Rel. Res.* 346, 26-37.


Yokouchi, Y., Sakiyama, J., Kameda, T., Iba, H., Suzuki, A., Ueno, N., and Kuroiwa, A. (1996). BMP-2/-4 mediate programmed cell death in chicken limb buds.
25 *Development* 122, 3725-3734.

Yoshimura, H. et al. (1995). A Novel Type of Retinoid Acid Receptor Antagonist: Synthesis and Structure-Activity Relationships of Heterocyclic Ring-Containing Benzoic Acid Derivatives. *J. Med. Chem.* 38, 3163-3173.

- 30 Zhang, H., and Bradley, A. (1996). Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* 122, 2977-2986.

Zou, H., and Niswander, L. (1996). Requirement for BMP signalling in interdigital apoptosis and scale formation. *Science* 272, 738-741.

- 5 Zou, H., Wieser, R., Massague, J., and Niswander, L. (1997). Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. *Genes & Dev.* 11, 2191-2203.



AGN 194301

2-Fluoro-4-[(1-(8-bromo-2,2-dimethyl-4-(4-methylphenyl)-
2-*H*-chromen-6-yl)-methanoyl)-amino]-benzoic acid

TABLE 1

Claims:

1. A composition for inducing chondrogenesis and/or skeletal development in a
5 vertebrate, the composition comprising:
 - (a) a RAR antagonist; and
 - (b) a pharmaceutically acceptable carrier.
2. The composition as claimed in claim 1, further comprising a protein selected
10 from the group consisting of a bone morphogenic protein (BMP), an osteogenic protein (OPS) and a cytokine and combinations thereof.
3. The composition as claimed in claim 2, wherein said BMP is selected from the
group consisting of BMP-2, BMP-4, and BMP-5.
- 15 4. The composition as claimed in claim 3, wherein said osteogenic protein is OP-1.
5. The composition of claim 1, wherein the RAR antagonist is present in an
20 amount capable of stimulating chondrogenesis and associated differentiation of skeletal progenitor cells.
6. The composition of claim 1, wherein said composition is provided as a
solution, suspension, gel, matrix, film, paste, pill, tablet or encapsulated within
25 liposomes.
7. The composition of claim 1, wherein said composition is administered via
intra-articular injection.
- 30 8. The composition of claim 1, wherein said composition is provided within a biodegradable implantable matrix.

9. The use of a composition comprising an RAR antagonist and a pharmaceutically acceptable carrier, for inducing chondrogenesis.
10. The use of a composition of claim 9 wherein said use is *in vitro*.
- 5 11. The use of a composition of claim 9 wherein said use is *in vivo*.
12. A morphogenic device for implantation in a vertebrate, the device comprising:
- 10 (a) an implantable biocompatible carrier; and
- (b) an RAR antagonist dispersed within or on said carrier.
13. The device according to claim 12, wherein said carrier comprises demineralized, protein-extracted, particulate, allogenic or xenogenic bone.
- 15 14. The device according to claim 12, wherein said device comprises mineral-free, delipidated Type I insoluble collagen.
15. The device according to claim 12, wherein said device comprises a biodegradable sponge.
- 20 16. A method for producing a chondrocyte from a chondroprogenitor mesenchymal cell comprising contacting said chondroprogenitor mesenchymal cell with an RAR antagonist agent *in vitro*.
- 25 17. A method for promoting *in vivo* integration of an implantable prosthetic device, into a target cartilage tissue of a vertebrate, the method comprising the steps of:
- (a) providing on a surface of the prosthetic device a composition comprising an RAR antagonist and a pharmaceutically acceptable carrier and
- 30 (b) implanting the device in a vertebrate, at a site where the target cartilage tissue and surface of the prosthetic device are maintained at least partially in contact

for a time sufficient to permit enhanced tissue growth between the target cartilage tissue and the device.

- 18 The method according to claim 19, wherein said target tissue is bone.
- 5 19. A method of treating a cartilage associated degenerative condition in a vertebrate comprising the step of administering a pharmaceutical composition as claimed in claim 1.
- 10 20. A method for promoting chondrogenesis and associated bone tissue formation at a site of skeletal surgery in a vertebrate, the method comprising the steps of delivering an RAR antagonist composition at the site of skeletal surgery wherein such delivery promotes the formation of new bone tissue.
- 15 21. A method for repairing large segmental skeletal gaps and non-union fractures arising from trauma or surgery in vertebrates, the method comprising delivering a RAR antagonist composition at the site of the segmental skeletal gap or non-union fracture wherein such delivery promotes chondrogenesis which mediates the formation of new bone tissue.
- 20 22. A method for aiding the attachment of implantable prosthesis at cartilaginous sites and for maintaining the long term stability of the prostheses in vertebrates, the method comprising coating selected regions of an implantable prosthesis with a RAR antagonist composition and implanting the coated prosthesis into a cartilaginous site
- 25 wherein such implantation promotes the formation of new cartilage tissue.
- 23 A method of producing cartilage at a cartilage defect *in vivo*, said method comprising:
- 30 - implanting into the defect a population of chondrogenic cells which have been cultured in the presence of a RAR antagonist

24. A method for treating degenerative joint disease characterized by cartilage degeneration, said method comprising:

- delivering a therapeutically effective amount of an RAR antagonist to the site of disease.

5

25. The method according to claim 24, wherein said RAR antagonist is delivered by intra-articular injection.

26. The method according to claim 24, wherein said disease is arthritis.

10

27. An implantable prosthetic device for repairing an orthopedic defect, injury or anomaly in a vertebrate, said device comprising:

(a) a prosthetic implant having a surface region implantable adjacent or within a target tissue;

15

(b) an RAR antagonist composition disposed on said surface region in an amount sufficient to promote enhanced chondrogenesis and associated bone tissue growth into the surface.

28. The use of a composition comprising an RAR antagonist for inhibiting RAR activity and stimulating chondroblast differentiation.

20

29. The use of an RAR antagonist for decreasing transcriptional activation of the RA receptor and stimulating chondroblast differentiation.




FIGURE 1

THIS PAGE BLANK (USPTO)




FIGURE 2A

THIS PAGE BLANK (USPTO)




FIGURE 2B

THIS PAGE BLANK (USPTO)

4/9




FIGURE 3A

THIS PAGE BLANK (USPTO)




FIGURE 3B-3I

THIS PAGE BLANK (USPTO)





FIGURE 4

THIS PAGE BLANK (USPTO)



FIGURES 5A - 5L

THIS PAGE BLANK (USPTO)

8/9




FIGURE 5M

THIS PAGE BLANK (USPTO)

9/9




FIGURE 6

NO. 1

THIS PAGE BLANK (USPTO)

TENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 6310-36/LAB	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 99/ 01106	International filing date (day/month/year) 19/11/1999	(Earliest) Priority Date (day/month/year) 19/11/1998
Applicant THE UNIVERSITY OF WESTERN ONT..et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING CHONDROGENESIS

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 99/01106

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/202 A61K31/203 A61K31/352 A61K31/192 A61K31/381
A61K31/196 A61K31/655 A61K31/382 A61K31/235 A61P19/02
A61P19/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	KOYAMA E ET AL: "Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis." DEVELOPMENTAL BIOLOGY, (1999 APR 15) 208 (2) 375-91. , XP000879298 page 386, column 1 -column 2 page 377, column 1, line 2	1,5,6,9, 10,16, 20,28,29
P, X	WO 99 24415 A (ITAI AKIKO ;HASHIMOTO YUICHI (JP); INST OF MEDICINAL MOLECULAR DE) 20 May 1999 (1999-05-20) abstract	1,5-11, 16,19-29
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "B" document member of the same patent family

Date of the actual completion of the international search

1 March 2000

Date of mailing of the international search report

10/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bonzano, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/01106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08546 A (INST NAT SANTE RECH MED ;UNIV PASTEUR (FR); CENTRE NAT RECH SCIENT) 5 March 1998 (1998-03-05) page 10 claims 1,10 page 26, line 1 -page 27, line 10	1,5-11, 16,19-29
X	US 5 827 500 A (JOMARD ANDRE ET AL) 27 October 1998 (1998-10-27) column 1, line 50 - line 62	1,5-11, 16,19-29
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP 10 114757 A (SHUDO KOICHI), 6 May 1998 (1998-05-06) abstract	1,5-11, 16,19-29
X	STANDEVEN A M ET AL: "Retinoid-induced epiphyseal plate closure in guinea pigs." FUNDAMENTAL AND APPLIED TOXICOLOGY, (1996 NOV) 34 (1) 91-8. , XP000879170 page 94, column 2 -page 95, column 1 page 92, column 2, paragraph 5 page 93, column 1, paragraph 2	1,5-16, 19-29
X	KOYAMA, E. ET AL: "Retinoids and their nuclear receptors promote the completion of chondrocyte maturation during limb skeletogenesis." MOLECULAR BIOLOGY OF THE CELL, (NOV., 1997) VOL. 8, NO. SUPPL., PP. 71A. MEETING INFO.: 37TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY WASHINGTON, D.C., USA DECEMBER 13-17, 1997 AMERICAN SOCIETY FOR CELL BIOLOGY. , XP000879148	1,5, 12-15
A	abstract	2-4, 6-11, 16-29

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/01106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>NUKA S (REPRINT) ET AL: "All-trans retinoic acid inhibits dexamethasone-induced ALP activity and mineralization in human osteoblastic cell line SV HFO"</p> <p>CELL STRUCTURE AND FUNCTION, (FEB 1997) VOL. 22, NO. 1, PP. 27-32. PUBLISHER: JAPAN SOC CELL BIOLOGY, SHIMOTACHIURI OGAWA-HIGASHI, KAMIKYOKU KYOTO 602, JAPAN. ISSN: 0386-7196., XP000879088</p> <p>SAPPORO MED UNIV, SCH MED, DEPT PATHOL, CHUO KU, S1, W17, SAPPORO, HOKKAIDO 060, JAPAN (Reprint); SAPPORO MED UNIV, SCH MED, DEPT ORTHOPAED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN</p> <p>page 31, column 2, paragraph 2</p>	<p>1,5-11, 16-23, 28,29</p>
Y	<p>VON SCHROEDER H P ET AL: "The effects of natural and synthetic retinoids on the differentiation of RCJ C5.18 chondrogenic cells."</p> <p>TERATOLOGY, (1994 JUL) 50 (1) 54-62. , XP000653320</p> <p>page 59, column 2, paragraph 1</p>	<p>1,5-11, 16-23, 28,29</p>
A	<p>JIANG: "Modulation of limb bud chondrogenesis by retinoic acid and retinoic acid receptors."</p> <p>DEVELOPMENTAL BIOLOGY, vol. 39, no. 4, 1995, XP000884176</p> <p>abstract</p> <p>page 620, column 1, paragraph 2 -page 621, column 2, paragraph 2</p> <p>page 622, column 1, paragraph 2</p> <p>page 623, column 1, paragraph 2</p>	<p>9-11, 16-26, 28,29</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/01106

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 9,11,17-26,28-29
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
SEE FURTHER INFORMATION PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/CA 99 01106

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-29 relate to compounds defined by reference to a desirable pharmacological property, namely the activity as antagonist of retinoic acid receptor.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is not fully possible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to their pharmacological profiles. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds structurally identified in the description, pp. 15-16, with due regard to the general idea underlying the present invention.

Claims searched completely: none.

Claims searched incompletely: 1-29.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/CA 99/01106

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9924415	A	20-05-1999	AU 1052599 A	31-05-1999
WO 9808546	A	05-03-1998	AU 4167497 A	19-03-1998
			EP 0928200 A	14-07-1999
			NO 990912 A	27-04-1999
US 5827500	A	27-10-1998	FR 2735371 A	20-12-1996
			EP 0749755 A	27-12-1996
JP 10114757	A	06-05-1998	NONE	

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 13 July 2000 (13.07.00)	
International application No. PCT/CA99/01106	Applicant's or agent's file reference 6310-36/LAB
International filing date (day/month/year) 19 November 1999 (19.11.99)	Priority date (day/month/year) 19 November 1998 (19.11.98)
Applicant UNDERHILL, Tully, Michael et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

09 June 2000 (09.06.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Nestor Santesso Telephone No.: (41-22) 338.83.38
---	---

THIS PAGE BLANK (USPTO)